The study's lead authors are David J. Libon, PhD, professor at the New Jersey Institute for Successful Aging at Rowan University, and Rod Swenson, PhD, clinical professor of Psychiatry and Behavioral Science at the University of North Dakota School of Medicine and Health Sciences. Both are advisors to Linus Health, which is revolutionizing brain health with science-driven digital solutions. The findings demonstrate how a 7-minute speech-based digital cognitive assessment from Linus Health captures quantifiable data on neurodegenerative disease risk based on patients' process of answering questions and test prompts.

In the peer-reviewed article, Libon and Swenson introduce a series of novel digital biomarkers based on latency -- the pauses and reaction times between actions -- when responding to questions or test prompts. They describe how subtle changes in the time required to respond -- even when answers are 100% correct -- can be interpreted as biomarkers for identifying the risk of mild cognitive impairment (MCI), Alzheimer's disease and other forms of dementia.

Published online June 30 in the journal Cell, the study revealed that holding closely together two protein groups (signaling complexes) on T cells, including one found more often on T cells involved autoimmune disease, shuts down those T cells in a limited way.

Led by researchers at NYU Langone Health, the Chinese Academy of Sciences, and Zhejiang University, the study built on biology newly discovered by the team to design an antibody that attached to both T cell signaling complexes, the T cell receptor and the LAG-3 checkpoint, held them closely together, and eliminated autoimmune tissue damage in three mouse models of disease.

Antibodies are proteins made by the immune system that label specific markers on cells for notice by the immune system. Researchers learned decades ago to engineer antibodies to target certain molecules as treatments, and more recently, antibodies that attach to two targets.

While the traditional way to administer protection has been to inject vaccines into the bloodstream, many experts called for developing a nasally delivered vaccine as a potentially more-effective approach. Now, encouraging results are in from the first human clinical trial to be conducted in the United States of a nasal COVID vaccine. Findings from the study led by an expert at Cincinnati Children's were published July 4, 2025, in Science Advances.

"A single dose of this vaccine (CVXGA) was well tolerated. It generated a wide spectrum of specific immune responses including mucosal and systemic immune responses. Those who received the highest dose of the vaccine showed significantly lower rates of symptomatic COVID-19 infection," says the study's lead author, Paul Spearman, MD, a long-time leader in vaccine research and vice chair for clinical and translational research and education at Cincinnati Children's.

A majority also expressed dissatisfaction with current home solar energy solutions from entrenched players on the market. While one of the key industry players remains the most recognized name in the space, nearly 24% of those familiar with the brand say they would not consider it. According to the poll, they cited shifting public sentiment and a desire for a less polarizing and more trustworthy solution.

The survey, commissioned by EcoFlow, found 60% of respondents wish to become less dependent on grid power and 70% said having a power backup solution is important. It also found 70% currently own or are interested in owning a solar battery solution in the future.

Solar and home backup batteries can offset utility costs and provide a source of household backup power during blackouts caused by natural disasters or other grid issues. Energy concerns have become top of mind in the U.S. due to an increasing number of natural disasters, rising electricity costs and more frequent power outages. These issues can be particularly acute for residents of California, Texas and Florida, who are often disproportionately impacted.

AeoniQ, a Swiss-based cleantech spin-off of HeiQ Materials AG, has developed the world's first climate-positive, biodegradable cellulosic filament yarn engineered to replace polyester and nylon. The AeoniQ platform is poised to disrupt the global textile industry by offering a fully circular, plastic-free alternative that mirrors the performance of synthetic fibers -- without their environmental toll.

As part of the agreement, the world's first industrial AeoniQ plant will be constructed at Altri's Caima pulp mill. Construction is expected to begin in 2026 with an initial capacity of 1.750 tons per year. On top of the already existing pilot lines in Austria, a pre-industrial plant will be launched in early 2026 in Portugal to accelerate prototyping, brand partnerships, and capsule collections.

A recent National Poll on Healthy Aging found that 75% of Americans over 65 report poor mental or physical health and feelings of loneliness, with isolation rates particularly high among those living alone. According to a recent inTouch survey, 47% of US caregivers indicated value in an AI service that would call their loved ones, especially seniors, on a daily basis and provide them with daily updates.

inTouch was born from founder Vassili Le Moigne's experience caring for his mother while living far away. "Even with the best intentions, it was difficult to call my mom on a daily basis while living and working across the country. I created inTouch so that she could have daily conversations that help her stay mentally active and independent. It was also a great way for her to keep me informed of her well-being," said Le Moigne.

"In Croatia, nearly half the population unknowingly faces potential spine issues. Reluctance to seek professional help has led to what is commonly known as a silent pandemic, hurting the nation's collective spine with alarming numbers. But now, we made sure the innovation steps in where the hesitation prevails," said Dr. Tatjana Kujundžic, head of Croatia Polyclinics.

Here's how it works: passers-by stand in front of an interactive digital billboard equipped with computer vision and AI-powered software. The system scans their posture by analyzing the alignment of the neck, mid-back, and lower spine through eight key points. Within seconds, it detects potential problems and provides immediate feedback, both visual and numeric, highlighting any areas of concern. If an issue is identified, the screen prompts the individual to book an appointment with a physiotherapist on the spot via a QR code, turning what might have been a casual wait for the bus into proactive health action.

Dr. DeArmitt's extensive analysis of thousands of peer-reviewed studies reveals that widespread myths about plastics are driving people toward choices that may actually harm their health and the environment. Dr. DeArmitt is committed to uncovering and communicating the truth about plastics, microplastics, and their health and environmental impact. "Shattering the Plastics Illusion" has also been peer-reviewed and endorsed by top scientists from around the world.

"Society has been fed myths about plastics by organizations that often have questionable motives," says Dr. DeArmitt. "It's time to be informed and ground our decisions in solid science rather than sensationalism so that we can finally implement solutions that genuinely benefit our environment."

Organised by German non-profit Onewater, with support from UNESCO's World Water Assessment Programme, MPB, the Asian Development Bank, and the City of Burghausen, the 2025 "Walk of Water" showcases a curated collection from highly decorated artists, including World Photography Awards winners and National Geographic explorers. Their powerful images span Alpine peaks, Himalayan communities, and polar expanses, capturing not only the stark reality of receding ice but also vibrant water festivals, indigenous adaptation strategies, and the profound cultural ties to these frozen landscapes—all threatened by a warming planet.

The loss of glaciers means rising sea levels, endangered drinking water and food production, and the disappearance of unique plants, animals, ecosystems and cultural heritage.

Once vision is lost, it cannot be recovered. If left untreated, glaucoma can cause blindness. That's why when it comes to detecting and treating glaucoma, the earlier, the better.
Glaucoma is an eye disease caused by increased pressure in the eye, which can damage the optic nerve and reduce vision, sometimes making objects look blurry or dark. Early on, most people don't notice what's happening, but as glaucoma progresses, you may notice some loss of peripheral vision. By this point, the disease has progressed significantly toward blindness, and treatment options may be limited.

Regular eye exams, including specific glaucoma tests, are important for the early detection and diagnosis of glaucoma. If diagnosed early, an eye doctor can recommend treatment to manage glaucoma and help prevent vision loss.